IMVT vs. VVNT, UTZ, ADV, CCIV, MPLN, NBIX, QGEN, RGEN, PCVX, and RVMD
Should you be buying Immunovant stock or one of its competitors? The main competitors of Immunovant include Vivint Smart Home (VVNT), Utz Brands (UTZ), Advantage Solutions (ADV), Churchill Capital Corp IV (CCIV), MultiPlan (MPLN), Neurocrine Biosciences (NBIX), Qiagen (QGEN), Repligen (RGEN), Vaxcyte (PCVX), and Revolution Medicines (RVMD).
Vivint Smart Home (NYSE:VVNT) and Immunovant (NASDAQ:IMVT) are both mid-cap retail/wholesale companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends, media sentiment, valuation and community ranking.
In the previous week, Immunovant had 26 more articles in the media than Vivint Smart Home. MarketBeat recorded 26 mentions for Immunovant and 0 mentions for Vivint Smart Home. Vivint Smart Home's average media sentiment score of 0.58 beat Immunovant's score of 0.00 indicating that Immunovant is being referred to more favorably in the news media.
Immunovant has a net margin of 0.00% compared to Immunovant's net margin of -3.07%. Immunovant's return on equity of 0.00% beat Vivint Smart Home's return on equity.
Vivint Smart Home has higher revenue and earnings than Immunovant. Vivint Smart Home is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks.
Vivint Smart Home has a beta of 0.99, suggesting that its share price is 1% less volatile than the S&P 500. Comparatively, Immunovant has a beta of 0.7, suggesting that its share price is 30% less volatile than the S&P 500.
Immunovant has a consensus target price of $49.00, indicating a potential upside of 92.99%. Given Vivint Smart Home's higher probable upside, analysts clearly believe Immunovant is more favorable than Vivint Smart Home.
47.1% of Immunovant shares are held by institutional investors. 8.6% of Vivint Smart Home shares are held by company insiders. Comparatively, 4.8% of Immunovant shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Immunovant received 69 more outperform votes than Vivint Smart Home when rated by MarketBeat users. Likewise, 76.55% of users gave Immunovant an outperform vote while only 51.85% of users gave Vivint Smart Home an outperform vote.
Summary
Immunovant beats Vivint Smart Home on 9 of the 16 factors compared between the two stocks.
Get Immunovant News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMVT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IMVT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Immunovant Competitors List
Related Companies and Tools
